Single-Pill, Two-Drug HIV treatment, JULUCA®, receives FDA nod

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved JULUCA(R), the first, complete, single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain adults living with the disease who are virologically suppressed. JULUCA(R) is a once-daily, antiretroviral combination of ["]

The post Single-Pill, Two-Drug HIV treatment, JULUCA(R), receives FDA nod appeared first on Outbreak News Today.